Great West Life Assurance Co. Can acquired a new position in shares of Xencor, Inc. (NASDAQ: XNCR – Get Rating ) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 76,521 shares of the biopharmaceutical company’s stock, valued at approximately $1,988,000. Great West Life Assurance Co. Can owned about 0.13% of Xencor as of its most recent SEC filing.
Other hedge funds have also recently bought and sold shares of the company. US Bancorp DE boosted its holdings in shares of Xencor by 324.9% in the second quarter. US Bancorp DE now owns 939 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 718 shares during the period. Nisa Investment Advisors LLC purchased a new position in shares of Xencor in the second quarter valued at approximately $27,000. Lazard Asset Management LLC boosted its holdings in shares of Xencor by 203.0% in the first quarter. Lazard Asset Management LLC now owns 4,485 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 3,005 shares during the period. KBC Group NV boosted its holdings in shares of Xencor by 71.1% in the second quarter. KBC Group NV now owns 5,070 shares of the biopharmaceutical company’s stock valued at $139,000 after purchasing an additional 2,106 shares during the period. Finally, Virtus ETF Advisers LLC boosted its holdings in shares of Xencor by 12.9% during the second quarter. Virtus ETF Advisers LLC now owns 5,185 shares of the biopharmaceutical company’s stock valued at $142,000 after purchasing an additional 593 shares during the period. 98.99% of the shares are currently owned by institutional investors and hedge funds.
Wall Street analysts forecast growth
A number of research analysts recently issued reports on the stock. Canaccord Genuity Group decreased their price objective on shares of Xencor from $50.00 to $48.00 in a research note on Wednesday, November 9th. Cowen assumed coverage on shares of Xencor in a research note on Tuesday, December 6th. They issued an “outperform” rating on the stock. Cowen assumed coverage on shares of Xencor in a research note on Tuesday, December 6th. They issued an “outperform” rating on the stock. StockNews.com raised shares of Xencor from a “sell” rating to a “hold” rating in a research note on Monday, November 14th. Finally, Raymond James upgraded shares of Xencor from an “outperform” rating to a “strong-buy” rating and set a $58.00 target price on the stock in a research note on Thursday, October 13th. One investment analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. Xencor presently has a consensus rating of “Buy” and a consensus target price of $47.50, based on data from MarketBeat.com.
Xencor Price Performance
Shares of Xencor stock opened at $32.50 on Friday. Xencor, Inc. has a fifty-two week low of $19.35 and a fifty-two week high of $35.92. The firm has a market cap of $1.95 billion, a P/E ratio of 67.71 and a beta of 0.65. The company’s 50-day moving average is $28.14, and its 200-day moving average is $28.17.
Xencor (NASDAQ:XNCR – Get Rating ) last posted its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.55) EPS for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.22. The company had revenue of $27.30 million for the quarter, compared to analyst estimates of $15.33 million. Xencor had a net margin of 10.07% and a return on equity of 4.04%. On average, analysts expect that Xencor, Inc. will report -1.61 earnings per share for the current year.
Xencor Insider Transactions
In other news, CMO Allen Yang sold 3,737 shares of Xencor stock in a transaction on Monday, December 19th. The shares were sold at an average price of $27.00, for a total transaction of $100,899.00. Following the transaction, the chief marketing officer now owns 63,521 shares in the company, valued at $1,715,067. The sale was disclosed in a document filed with the SEC, which is available on the SEC’s website. 4.23% of shares are owned by company insiders.
Xencor, Inc. is a biopharmaceutical company engaged in the development of engineered monoclonal antibody therapeutics for the treatment of severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody candidates designed to treat autoimmune and allergic diseases, cancer and other conditions.
This instant news alert is generated by narrative science technology and financial data from MarketBeat to provide readers with the fastest and most accurate reporting. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Xencor, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients daily. MarketBeat identified the five stocks that top analysts are quietly whispering to their clients to buy now, before the broader market takes a nosedive … and Xencor wasn’t on the list.
While Xencor currently has a “Buy” rating among analysts, the top-rated analysts think these five stocks are better buys.
Check out the five stocks here